Article ; Online: Next generation of immune checkpoint molecules in maternal-fetal immunity.
2022 Volume 308, Issue 1, Page(s) 40–54
Abstract: Successful pregnancy is a unique situation requires the maternal immune system to recognize and tolerate a semi-identical fetus and allow normal invasion of trophoblast cells. Although efforts have been made, the deep mechanisms of the maternal-fetal ... ...
Abstract | Successful pregnancy is a unique situation requires the maternal immune system to recognize and tolerate a semi-identical fetus and allow normal invasion of trophoblast cells. Although efforts have been made, the deep mechanisms of the maternal-fetal crosstalk have not yet been fully deciphered. Immune checkpoint molecules (ICMs) are a group of negative modulators of the immune response that avoid immune damage. They have been extensively studied in the fields of oncology and transplantation, while the latest evidence suggests that they are closely associated with pregnancy outcomes via multiple inhibitory mechanisms. Although studies have mostly demonstrated the regulatory role of the well-known PD-1, CTLA-4 at the maternal-fetal interface, what is unique about the newly discovered multiple ICMs remains a mystery. Here, we review the latest knowledge on ICMs, focusing on the first generation of checkpoints (PD-1, CTLA-4) and the next generation (Tim-3, Tigit, Lag-3, VISTA) highlighting their immunoregulatory roles in maternal-fetal tolerance and decidual vascular remodeling, and their involvement in pathological pregnancies. The content covers three aspects: the characteristics they possess, the dynamic expression profile of their expression at the maternal-fetal interface, and their involvement in pathological pregnancy. In immunotherapy strategies for pregnancy complications, upregulation of immune checkpoints may play a role. Meanwhile, the impact on pregnancy outcomes when using ICMs in clinical cancer treatment during pregnancy is a topic worth exploring. These may serve as a guide for future basic research and clinical applications of maternal-fetal immunity. |
---|---|
MeSH term(s) | CTLA-4 Antigen ; Female ; Humans ; Immune Checkpoint Proteins/genetics ; Immune Tolerance ; Immunity ; Pregnancy ; Programmed Cell Death 1 Receptor/metabolism |
Chemical Substances | CTLA-4 Antigen ; Immune Checkpoint Proteins ; Programmed Cell Death 1 Receptor |
Language | English |
Publishing date | 2022-03-02 |
Publishing country | England |
Document type | Journal Article ; Review ; Research Support, Non-U.S. Gov't |
ZDB-ID | 391796-4 |
ISSN | 1600-065X ; 0105-2896 |
ISSN (online) | 1600-065X |
ISSN | 0105-2896 |
DOI | 10.1111/imr.13073 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Se 160: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.